DBV Technologies (DBVT) Competitors $9.46 -0.03 (-0.31%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DBVT vs. LENZ, ZYME, SYRE, UPB, STOK, VERV, PRAX, VALN, CRMD, and MLYSShould you be buying DBV Technologies stock or one of its competitors? The main competitors of DBV Technologies include LENZ Therapeutics (LENZ), Zymeworks (ZYME), Spyre Therapeutics (SYRE), Upstream Bio (UPB), Stoke Therapeutics (STOK), Verve Therapeutics (VERV), Praxis Precision Medicines (PRAX), Valneva (VALN), CorMedix (CRMD), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry. DBV Technologies vs. Its Competitors LENZ Therapeutics Zymeworks Spyre Therapeutics Upstream Bio Stoke Therapeutics Verve Therapeutics Praxis Precision Medicines Valneva CorMedix Mineralys Therapeutics LENZ Therapeutics (NASDAQ:LENZ) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk. Do analysts prefer LENZ or DBVT? LENZ Therapeutics presently has a consensus target price of $49.60, indicating a potential upside of 29.84%. DBV Technologies has a consensus target price of $14.75, indicating a potential upside of 56.25%. Given DBV Technologies' higher probable upside, analysts plainly believe DBV Technologies is more favorable than LENZ Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LENZ Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17DBV Technologies 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Which has more volatility & risk, LENZ or DBVT? LENZ Therapeutics has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500. Comparatively, DBV Technologies has a beta of -0.58, indicating that its share price is 158% less volatile than the S&P 500. Which has stronger valuation & earnings, LENZ or DBVT? LENZ Therapeutics is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLENZ TherapeuticsN/AN/A-$49.77M-$1.90-20.11DBV TechnologiesN/AN/A-$113.92M-$4.77-1.98 Do insiders & institutionals have more ownership in LENZ or DBVT? 54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 71.7% of DBV Technologies shares are held by institutional investors. 6.9% of LENZ Therapeutics shares are held by insiders. Comparatively, 1.4% of DBV Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media refer more to LENZ or DBVT? In the previous week, LENZ Therapeutics had 2 more articles in the media than DBV Technologies. MarketBeat recorded 4 mentions for LENZ Therapeutics and 2 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.47 beat LENZ Therapeutics' score of 0.85 indicating that DBV Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENZ Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DBV Technologies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is LENZ or DBVT more profitable? LENZ Therapeutics has a net margin of 0.00% compared to DBV Technologies' net margin of -3,220.49%. LENZ Therapeutics' return on equity of -25.63% beat DBV Technologies' return on equity.Company Net Margins Return on Equity Return on Assets LENZ TherapeuticsN/A -25.63% -24.43% DBV Technologies -3,220.49%-287.15%-138.83% SummaryLENZ Therapeutics beats DBV Technologies on 10 of the 14 factors compared between the two stocks. Get DBV Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DBVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DBVT vs. The Competition Export to ExcelMetricDBV TechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$258.56M$3.06B$5.76B$9.84BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-1.9821.2231.3126.60Price / SalesN/A390.30461.30121.37Price / CashN/A44.4437.7659.36Price / Book3.008.0710.026.67Net Income-$113.92M-$54.08M$3.27B$265.59M7 Day Performance-1.05%2.26%3.17%3.42%1 Month Performance-4.21%3.42%4.34%1.09%1 Year Performance117.01%18.61%44.11%23.85% DBV Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DBVTDBV Technologies3.393 of 5 stars$9.44-0.5%$14.75+56.3%+111.9%$258.56MN/A-1.9880Positive NewsGap DownLENZLENZ Therapeutics1.8078 of 5 stars$38.77+2.4%$49.60+27.9%+69.9%$1.08BN/A-20.41110ZYMEZymeworks0.0446 of 5 stars$14.05-2.2%N/AN/A$1.08B$76.30M-14.48460SYRESpyre Therapeutics3.085 of 5 stars$16.94-0.1%$53.40+215.2%-38.4%$1.02B$890K-4.9873News CoveragePositive NewsUPBUpstream Bio2.3164 of 5 stars$18.02-4.8%$56.50+213.5%N/A$1.02B$2.37M0.0038STOKStoke Therapeutics4.4765 of 5 stars$18.51+1.6%$25.57+38.1%+39.1%$997.86M$36.56M21.78100VERVVerve Therapeutics2.7622 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110PRAXPraxis Precision Medicines1.7013 of 5 stars$46.63-1.0%$85.88+84.2%-12.3%$990.84M$8.55M-3.79110VALNValneva2.0741 of 5 stars$12.14+5.3%$15.50+27.7%+14.5%$981.14M$183.52M-12.39700Analyst ForecastGap UpCRMDCorMedix2.7079 of 5 stars$13.10+1.3%$16.71+27.6%+129.2%$965.21M$43.47M17.4730MLYSMineralys Therapeutics3.2601 of 5 stars$15.34+5.6%$32.25+110.2%+24.7%$962.61MN/A-4.3128Analyst Forecast Related Companies and Tools Related Companies LENZ Therapeutics Alternatives Zymeworks Alternatives Spyre Therapeutics Alternatives Upstream Bio Alternatives Stoke Therapeutics Alternatives Verve Therapeutics Alternatives Praxis Precision Medicines Alternatives Valneva Alternatives CorMedix Alternatives Mineralys Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DBVT) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DBV Technologies S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share DBV Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access